New approach aims to shield patients from Transplant's dangerous side effects
NCT ID NCT06265584
Summary
This study is testing whether changing the timing of a key immune-suppressing drug (ATG) can better prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The goal is to allow the donor cells to fight the cancer (graft-versus-leukemia effect) while reducing damage to the patient's body. Researchers will combine this modified ATG schedule with standard medications (tacrolimus and mini methotrexate) in 56 adults with acute leukemia, myelodysplastic syndrome, or myeloproliferative disorders.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.